CN104435877A - Radix-puerariae-containing pharmaceutical composition for reducing blood fat - Google Patents

Radix-puerariae-containing pharmaceutical composition for reducing blood fat Download PDF

Info

Publication number
CN104435877A
CN104435877A CN201410626431.9A CN201410626431A CN104435877A CN 104435877 A CN104435877 A CN 104435877A CN 201410626431 A CN201410626431 A CN 201410626431A CN 104435877 A CN104435877 A CN 104435877A
Authority
CN
China
Prior art keywords
parts
pharmaceutical composition
radix
puerariae
raw material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410626431.9A
Other languages
Chinese (zh)
Inventor
李文军
张太君
成建国
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHENGDU GUORUI PHARMACEUTICAL TECHNOLOGY Co Ltd
Original Assignee
CHENGDU GUORUI PHARMACEUTICAL TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHENGDU GUORUI PHARMACEUTICAL TECHNOLOGY Co Ltd filed Critical CHENGDU GUORUI PHARMACEUTICAL TECHNOLOGY Co Ltd
Priority to CN201410626431.9A priority Critical patent/CN104435877A/en
Publication of CN104435877A publication Critical patent/CN104435877A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/894—Dioscoreaceae (Yam family)
    • A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8994—Coix (Job's tears)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a radix-puerariae-containing pharmaceutical composition for reducing blood fat. The radix-puerariae-containing pharmaceutical composition is prepared from raw materials including phoenix tree leaves, semen coicis, polygonum multiflorum, Chinese yams, radix puerariae, ginkgo leaves and cattail pollen. Verified by pharmacologic experiments, the pharmaceutical composition disclosed by the invention has a favorable blood fat reducing effect and is exact in curative effect, small in dosage, free of toxic or side effects on a human body, simple in prescription and beneficial to popularization and application.

Description

The pharmaceutical composition for blood fat reducing containing Radix Puerariae
Technical field
The present invention relates to a kind of pharmaceutical composition of blood fat reducing, particularly a kind of is the pharmaceutical composition that raw material is made by Folium firmianae, Semen Coicis, Radix Polygoni Multiflori, Rhizoma Dioscoreae, Radix Puerariae, Folium Ginkgo and Pollen Typhae.
Background technology
Along with improving constantly of people's living standard, the sickness rate of hyperlipemia is obvious ascendant trend, and hyperlipemia is again the key factor of bringing out coronary atherosclerotic heart disease (coronary heart disease), arteriosclerosis, fatty liver, diabetes, obesity etc.Therefore the blood lipid-lowering medicine finding high effect nontoxic has important realistic meaning.
Lipoprotein refers to the protein together with contaminated with lipid, comprise very low density lipoprotein (VLDL) (VLDL), low density lipoprotein, LDL (LDL), high density lipoprotein (HDL), the lipid of different lipoprotein forms the difference mainly measured, the difference of rarer matter.The chemical composition 80% ~ 90% of very low density lipoprotein (VLDL) is triacylglycerol, is the important form of body transport endogenous triacylglycerol, so when very low density lipoprotein (VLDL) raises, triacylglycerol also must raise; Low density lipoprotein, LDL is that its molecule is minimum, and cholesterol level is the highest, so when low density lipoprotein, LDL increases, cholesterol total amount must increase by the principal mode of the cholesterol transport of liver synthesis to body tissue; High density lipoprotein granule is less, protein content is the highest, can more freely to come in and go out tremulous pulse, can excrete after carrying out metabolism in the reverse cholesterol transport on arterial wall to liver, reduce the deposition of cholesterol on arterial wall, the minimizing of high density lipoprotein just means increasing of cholesterol total amount.
The Western medicine being used for the treatment of hyperlipemia is at present subject to everybody favor certainly because of its rapid-action and curative effect, but Western medicine has toxic and side effects in various degree, and Chinese medicine is in treatment hyperlipemia, prevent the aspects such as cardiovascular and cerebrovascular disease generation from having unique advantage, its curative effect certainly, lasting, side effect is little, is that Western medicine institute is incomparable.Particularly in differentiation of symptoms and signs for classification of syndrome, embody the flexible prescription of the traditional Chinese medical science, the therapeutic features of giving treatment in accordance with the patient’s individuality.Modern doctor generally believes genus deficiency in origin and excess in superficiality, blood stasis, the turbid category of expectorant for the understanding of hyperlipemia; Ahyperlipoidemia name of disease in Chinese medicine, clinical syndrome differentiation is attributed to caused by liver and kidney deficiency more, and insufficiency of the spleen expectorant is turbid, qi depression to blood stasis.Large multiplex liver and kidney tonifying during treatment, invigorating the spleen and benefiting QI, nourishing YIN and benefiting blood, blood circulation promoting and blood stasis dispelling, clearing away heat and loosing the bowels, eliminate indigestion and phlegm these medicines.
At present, treatment hyperlipemia Chinese patent medicine more, this wherein, some prescriptions are excessive, and curative effect is indefinite, and what have causes price quite high owing to employing rare medicinal herbs in side.These all make to be unfavorable for that promotion price is applied.
Summary of the invention
The object of the invention is to overcome above-mentioned deficiency existing in prior art, a kind of pharmaceutical composition for blood fat reducing containing Radix Puerariae is provided.This pharmaceutical composition has good blood fat reducing function, determined curative effect, and dosage is little, and to human non-toxic's side effect, and prescription is simple, is beneficial to and applies.
In order to realize foregoing invention object, the invention provides following technical scheme:
The pharmaceutical composition for blood fat reducing containing Radix Puerariae of the present invention, it is the medicament be made up of following raw material: Folium firmianae, Semen Coicis, Radix Polygoni Multiflori, Rhizoma Dioscoreae, Radix Puerariae, Folium Ginkgo and Pollen Typhae.
In pharmaceutical composition of the present invention, Folium firmianae is bitter; Cold; Return lung; Liver Channel.For rheumatic arthralgia; Traumatic injury; Carbuncle pyogenic infections from tumour or sore; Hemorrhoid; Infantile malnutrition; Dysentery; Hypertension.
Semen Coicis, cool in nature, sweet in the mouth, light.There is spleen invigorating eliminating dampness by diuresis, eliminating impediment antidiarrheal.For effect of edema, beriberi, dysuria, arthralgia chiefly caused by damp pathogen contracture, diarrhea due to hypofunction of the spleen.
Radix Polygoni Multiflori, bitter sweet puckery, tepor; Enter spleen, lung, kidney three warp; Nourishing the blood and yin; Loosening bowel to relieve constipation; Preventing the attack (or recurrence) of malaria; Dispel the wind; Removing toxic substances; Main blood deficiency Light-headedness; Cardiopalmus; Insomnia; The soreness of the waist and knees of the hepatic and renal YIN deficiency; Early whitening of beard and hair; Tinnitus; Seminal emission; Dryness of the intestine constipation; Chronic malaria body is empty; Rubella pruritus; Carbuncle sore; Scrofula; Hemorrhoid.
Rhizoma Dioscoreae is sweet, flat, nontoxic; Return spleen, lung, kidney channel.Spleen reinforcing nourishing the stomach, promote the production of body fluid lung benefiting, the kidney invigorating arresting seminal emission.For insufficiency of the spleen lack of appetite, incessant chronic diarrhea, the deficiency of the lung is breathed with cough, emission due to deficiency of the kidney, leukorrhagia, frequent micturition, and deficiency-heat is quenched one's thirst; Rhizoma Dioscoreae (parched with bran) spleen reinforcing stomach invigorating.For insufficiency of the spleen lack of appetite, loose stool of having loose bowels, leukorrhagia.
Radix Puerariae, having induces sweat brings down a fever, the function of promoting the production of body fluid to quench thirst, antidiarrheal, and can improve the symptom such as stiffness of the nape, dizziness, headache, tinnitus of hypertensive patient.
Folium Ginkgo, mildly bitter flavor, property is put down.There is the beneficial heart, promoting blood circulation and stopping pain, astringe the lung relieving asthma, effect of removing dampness antidiarrheal.
Pollen Typhae, returns liver; The heart; Spleen channel.Hemostasis, blood stasis dispelling, treating stranguria.For haematemesis, epistaxis, spitting of blood, metrorrhagia, traumatic hemorrhage, amenorrhea, dysmenorrhea, gastral cavity ventral spine pain, treating swelling and pain by traumatic injury, the wet pain of stranguria with blood.
Applicant finds through test of many times, is that pharmaceutical composition made by raw material by Folium firmianae, Semen Coicis, Radix Polygoni Multiflori, Rhizoma Dioscoreae, Radix Puerariae, Folium Ginkgo and Pollen Typhae, can effectively blood fat reducing.
Preferably, described pharmaceutical composition is made up of the raw material of following weight: Folium firmianae 5 ~ 20 parts, Semen Coicis 5 ~ 15 parts, Radix Polygoni Multiflori 4 ~ 12 parts, Rhizoma Dioscoreae 1 ~ 10 part, Radix Puerariae 1 ~ 10 part, Folium Ginkgo 1 ~ 7 part and Pollen Typhae 1 ~ 7 part.
Applicant finds through many experiments, and pharmaceutical composition of the present invention is made up of the raw material of above-mentioned weight, better can play the synergistic function of each raw material components, not only can effectively blood fat reducing, simultaneously instant effect, and dosage is little, has no side effect.
Further preferably, described pharmaceutical composition is made up of the raw material of following weight: Folium firmianae 6 ~ 15 parts, Semen Coicis 8 ~ 14 parts, Radix Polygoni Multiflori 5 ~ 10 parts, Rhizoma Dioscoreae 3 ~ 8 parts, Radix Puerariae 3 ~ 8 parts, Folium Ginkgo 1 ~ 6 part and Pollen Typhae 2 ~ 6 parts.
Still more preferably, described pharmaceutical composition is made up of the raw material of following weight: Folium firmianae 10 ~ 12 parts, Semen Coicis 8 ~ 10 parts, Radix Polygoni Multiflori 7 ~ 9 parts, Rhizoma Dioscoreae 4 ~ 7 parts, Radix Puerariae 5 ~ 6 parts, Folium Ginkgo 1 ~ 3 part and Pollen Typhae 2 ~ 3 parts.
Preferably, to the best described pharmaceutical composition be made up of the raw material of following weight: Folium firmianae 12 parts, Semen Coicis 9 parts, Radix Polygoni Multiflori 9 parts, Rhizoma Dioscoreae 6 parts, Radix Puerariae 6 parts, Folium Ginkgo 3 parts and Pollen Typhae 3 parts.
By preferably above, the curative effect of pharmaceutical composition can be improved further.
The dosage form of pharmaceutical composition of the present invention can be the existing pharmaceutical dosage form of any one in drop pill, tablet, capsule, soft capsule, powder, oral liquid, granule.
The preparation method of pharmaceutical composition of the present invention is as follows:
The raw material of above-mentioned weight is added respectively 50 ~ 70% ethanol of 8 ~ 10 times of volumes, reflux, extract, three times, extraction time is respectively 2.0h, 1.5h, 1.5h, filter, merge 3 filtrates, by each concentrated solution mix homogeneously after recovery ethanol also concentrates, dry, make acceptable various pharmaceutical dosage form.
According to the needs of the various drug form of preparation, medicine of the present invention also can add suitable pharmaceutic adjuvant as filler, disintegrating agent, binding agent, lubricant, antiseptic etc. in preparation process.
Preparation method of the present invention effectively can extract the effective ingredient in each crude drug, makes it better play the effect of Synergistic.
The present invention's various raw medicinal materials used are the Chinese crude drug meeting country or provincial standard and specify.The pharmaceutical composition of blood fat reducing of the present invention, based on theory of Chinese medical science, in conjunction with clinical practice, from Chinese medicine material treasure-house, filter out Folium firmianae, Semen Coicis, Radix Polygoni Multiflori, Rhizoma Dioscoreae, Radix Puerariae, Folium Ginkgo and the pure purification of tcm of Pollen Typhae seven taste form, and regulate the weight of each raw material, and make the effect playing Synergistic between each raw material, can effectively blood fat reducing, heat clearing away suppressing the hyperactive liver, reduces phlegm and invigorates blood circulation.Pharmaceutical composition instant effect of the present invention simultaneously, dosage is little, has no side effect.
Detailed description of the invention
Below in conjunction with test example and detailed description of the invention, the present invention is described in further detail.But this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following embodiment, all technology realized based on content of the present invention all belong to scope of the present invention.
Embodiment 1
The pharmaceutical composition of the blood fat reducing described in the present embodiment, be made up of the raw material of following weight:
Folium firmianae 12g, Semen Coicis 9g, Radix Polygoni Multiflori 9g, Rhizoma Dioscoreae 6g, Radix Puerariae 6g, Folium Ginkgo 3g and Pollen Typhae 3g.
Above-mentioned raw materials is prepared into granule, and preparation method is as follows:
The raw material of above-mentioned weight is added respectively 70% ethanol of 10 times of volumes, reflux, extract, three times, extraction time is respectively 2.0h, 1.5h, 1.5h, filter, merge 3 filtrates, by each concentrated solution mix homogeneously after recovery ethanol also concentrates, dry, add 200g dextrin, make granule according to the preparation technique of granule, be distributed into bag.
Embodiment 2
The pharmaceutical composition of blood fat reducing described in the present embodiment, be made up of the raw material of following weight:
Folium firmianae 5g, Semen Coicis 5g, Radix Polygoni Multiflori 4g, Rhizoma Dioscoreae 1g, Radix Puerariae 1g, Folium Ginkgo 1g and Pollen Typhae 1g.
Above-mentioned raw materials is prepared into tablet, and preparation method is as follows:
The raw material of above-mentioned weight is added respectively 60% ethanol of 8 times of volumes, reflux, extract, three times, extraction time is respectively 2.0h, 1.5h, 1.5h, filters, merges 3 filtrates, by each concentrated solution mix homogeneously after recovery ethanol also concentrates, drying, then with 140 starch, 20g polyvidone mixes, adopt existing pressed-disc technique, make the pharmaceutical composition of tablet.
Embodiment 3
The pharmaceutical composition of blood fat reducing described in the present embodiment, be made up of the raw material of following weight:
Folium firmianae 20g, Semen Coicis 15g, Radix Polygoni Multiflori 12g, Rhizoma Dioscoreae 10g, Radix Puerariae 10g, Folium Ginkgo 7g and Pollen Typhae 3g.
Above-mentioned raw materials is prepared into powder, and preparation method is as follows:
The raw material of above-mentioned weight is added respectively 60% ethanol of 8 times of volumes, reflux, extract, three times, extraction time is respectively 2.0h, 1.5h, 1.5h, filters, merges 3 filtrates, by each concentrated solution mix homogeneously after recovery ethanol also concentrates, drying, then with 180g sucrose, mixing, according to the preparation technique of powder, make powder.
Embodiment 4
The pharmaceutical composition of blood fat reducing described in the present embodiment, be made up of the raw material of following weight:
Folium firmianae 15g, Semen Coicis 10g, Radix Polygoni Multiflori 5g, Rhizoma Dioscoreae 8g, Radix Puerariae 7g, Folium Ginkgo 6g and Pollen Typhae 4g.
Above-mentioned raw materials is prepared into capsule, and preparation method is as follows:
The raw material of above-mentioned weight is added respectively 60% ethanol of 8 times of volumes, reflux, extract, three times, extraction time is respectively 2.0h, 1.5h, 1.5h, filters, merges 3 filtrates, by each concentrated solution mix homogeneously after recovery ethanol also concentrates, drying, then with 30g vegetable oil, mixing, using ' Yanming ' capsules for clearing as capsule casing material, make soft capsule.
Comparative example 1
The pharmaceutical composition of the blood fat reducing described in this comparative example, be made up of the raw material of following weight:
Folium firmianae 12g, Semen Coicis 9g, Radix Polygoni Multiflori 9g, Rhizoma Dioscoreae 6g, Folium Ginkgo 3g and Pollen Typhae 3g.
Adopt the preparation method described in embodiment 1, make the pharmaceutical composition of granule.
Comparative example 2
The pharmaceutical composition of the blood fat reducing described in this comparative example, be made up of the raw material of following weight:
Folium firmianae 12g, Radix Polygoni Multiflori 9g, Rhizoma Dioscoreae 6g, Radix Puerariae 6g, Folium Ginkgo 3g and Pollen Typhae 3g.
Adopt the preparation method described in embodiment 1, make the pharmaceutical composition of granule.
Embodiment 5
1. laboratory animal: healthy Kunming mouse, body weight 20-25g, male and female half and half;
2, Experimental agents: cholesterol, propylthiouracil.
3, experiment grouping:
Get healthy Kunming mouse 80, be divided into 8 groups at random, namely blank group, model group, positive drug group (administration simvastatin), embodiment 1 group (administration embodiment 1 prepare pharmaceutical composition), embodiment 2 groups (pharmaceutical composition prepared by administration embodiment 2), embodiment 3 groups (pharmaceutical composition prepared by administration embodiment 3), comparative example 1 group (pharmaceutical composition prepared by administration comparative example 1), comparative example 2 groups (pharmaceutical composition prepared by administration comparative example 2), often organize 10, male and female half and half.
Each group of morning gives gastric infusion, gavage solution is prepared with 2% tween solution, gavage capacity 20ml/kgBW, each group of embodiment 1-3, comparative example 1-2 respectively organize dosage and are 10g/kg by crude drug gauge, the dosage of simvastatin is 0.04g/kg, and blank, model group gives equivalent 2% tween solution.
4, experimental technique:
The preparation of 4.1 fat milks:
Get 1g propylthiouracil porphyrize in mortar, for subsequent use; Get 20g Adeps Sus domestica to melt in 40 DEG C of heating in water bath, put in mortar, add 10g cholesterol, 1g propylthiouracil, fully stir, dissolve; Slowly add 10% deoxycholic acid sodium water solution 20ml again, and constantly stir, then add 5ml Tween 80, grinding emulsifying is even, and last adding distil water is to 100ml; Load in hermetic container, cold preservation, obtains fat milk.Fat milk is melting prior to 37 DEG C of water-baths before use.
4.2 modeling methods: except blank group, all the other are respectively organized mice and all give gavage fat milk 20ml/kgBW, continuous 2 weeks.
5, Testing index
TG, TC level determination in 5.1 serum: after last gavage, water 12h is can't help in fasting, gets blood, according to test kit, mensuration TC, TG level is described.
MDA content and SOD determination of activity in 5.2 livers: mice is put to death after getting blood, wins liver 0.5g, rinses in normal saline, filter paper blots, make the liver homogenate liquid of 10% with normal saline homogenate, centrifuging and taking supernatant, illustrate according to test kit and measure MDA content and SOD activity.
6. statistical method: adopt SPSS13.0 software to carry out one factor analysis of variance to experimental data, every data all with represent.
7, result:
7.1 impacts on serum TC, TG level: in table 1
Table 1: pharmaceutical composition of the present invention on the impact of mice serum TC, TG ( n=10)
Group Dosage (g/kg) TC(mmol/L) TG(mmol/L)
Normal group / 2.98±0.59 0.44±0.21
Model group / 5.24±0.62 ## 0.81±0.18 ##
Positive controls 0.04 3.59±0.58 ** 0.55±0.19 *
Embodiment 1 group 10 3.70±0.61 **&▲ 0.61±0.22
Embodiment 2 groups 10 3.84±0.58 **&▲ 0.67±0.18
Embodiment 3 groups 10 3.78±0.62 **&▲ 0.65±0.17
Comparative example 1 group 10 4.72±0.57 * 0.73±0.16
Comparative example 2 groups 10 4.69±0.61 * 0.72±0.21
Note: compare with normal group, ##p < 0.01; Compare with model group, *p < 0.05, *p < 0.01; Compared with comparative example 1 group, aMP.AMp.Ampp < 0.05; Compared with comparative example 2 groups, ▲p < 0.05.
Table 1 result shows:
Compare with normal group, in model group mice serum, TC and TG content is in various degree higher than normal group, and difference has statistical significance (P < 0.01), shows modeling success.
Compare with model group, positive controls reduces the content of TC, TG in mice serum, has significant difference (P < 0.01); Compare with model group, embodiment 1-3 group reduces TC and TG content, has significant difference (P < 0.01), shows that pharmaceutical composition of the present invention can effectively blood fat reducing.
Compare with 2 groups with comparative example 1, embodiment 1-3 respectively organizes TC and TG content in mice serum and obviously reduces (P < 0.05); Show in pharmaceutical composition of the present invention to be Synergistic between each raw material, lack effect that any Herba indigoferae Pseudotinctoriae all significantly can reduce pharmaceutical composition.
7.2 impacts on liver MDA content and SOD activity: in table 2
Table 2: on the impact of liver MDA content and SOD activity ( n=10)
Group Dosage (g/kg) MDA(nmol/ml) SOD(U/ml)
Normal group / 3.82±1.18 185.26±11.29
Model group / 7.51±1.20 ## 138.34±12.01 ##
Positive controls 0.04 4.01±1.19 ** 179.36±11.56 **
Embodiment 1 group 10 4.72±1.18 **&▲ 174.21±12.49 **&▲
Embodiment 2 groups 10 4.89±1.22 **&▲ 171.46±11.75 **&▲
Embodiment 3 groups 10 4.95±1.19 **&▲ 169.18±12.05 **&▲
Comparative example 1 group 10 6.30±1.21 * 153.68±11.68 *
Comparative example 2 groups 10 6.27±1.17 * 151.24±12.13 *
Note: compare with normal group, ##p < 0.01; Compare with model group, *p < 0.05, *p < 0.01; Compared with comparative example 1 group, aMP.AMp.Ampp < 0.05; Compared with comparative example 2 groups, ▲p < 0.05.
Table 2 result shows:
Compare with normal group, in model group mouse liver, MDA content significantly raises, and SOD is active significantly reduces (P < 0.01), shows modeling success.
Compare with model group, positive controls MDA content obviously reduces, and SOD is active obviously raises (P < 0.01); Compare with model group, embodiment 1-3 group MDA content significantly reduces, and SOD is active significantly raises (P < 0.01), shows that pharmaceutical composition of the present invention can effectively blood fat reducing.
Compared with comparative example 1-2 group, embodiment 1-3 respectively organizes MDA content in mouse liver and obviously reduces, SOD is active obviously raises (P < 0.05), show in pharmaceutical composition of the present invention to be Synergistic between each raw material, lack effect that any Herba indigoferae Pseudotinctoriae all significantly can reduce pharmaceutical composition.

Claims (5)

1. the pharmaceutical composition for blood fat reducing containing Radix Puerariae, it is characterized in that, it is the medicament be made up of following raw material: Folium firmianae, Semen Coicis, Radix Polygoni Multiflori, Rhizoma Dioscoreae, Radix Puerariae, Folium Ginkgo and Pollen Typhae.
2. pharmaceutical composition according to claim 1, it is characterized in that, the weight of described each raw material is: Folium firmianae 5 ~ 20 parts, Semen Coicis 5 ~ 15 parts, Radix Polygoni Multiflori 4 ~ 12 parts, Rhizoma Dioscoreae 1 ~ 10 part, Radix Puerariae 1 ~ 10 part, Folium Ginkgo 1 ~ 7 part and Pollen Typhae 1 ~ 7 part.
3. pharmaceutical composition according to claim 2, it is characterized in that, the weight of described each raw material is: Folium firmianae 6 ~ 15 parts, Semen Coicis 8 ~ 14 parts, Radix Polygoni Multiflori 5 ~ 10 parts, Rhizoma Dioscoreae 3 ~ 8 parts, Radix Puerariae 3 ~ 8 parts, Folium Ginkgo 1 ~ 6 part and Pollen Typhae 2 ~ 6 parts.
4. pharmaceutical composition according to claim 3, it is characterized in that, the weight of described each raw material is: Folium firmianae 10 ~ 12 parts, Semen Coicis 8 ~ 10 parts, Radix Polygoni Multiflori 7 ~ 9 parts, Rhizoma Dioscoreae 4 ~ 7 parts, Radix Puerariae 5 ~ 6 parts, Folium Ginkgo 1 ~ 3 part and Pollen Typhae 2 ~ 3 parts.
5. pharmaceutical composition according to claim 4, is characterized in that, the weight of described each raw material is: Folium firmianae 12 parts, Semen Coicis 9 parts, Radix Polygoni Multiflori 9 parts, Rhizoma Dioscoreae 6 parts, Radix Puerariae 6 parts, Folium Ginkgo 3 parts and Pollen Typhae 3 parts.
CN201410626431.9A 2014-11-10 2014-11-10 Radix-puerariae-containing pharmaceutical composition for reducing blood fat Pending CN104435877A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410626431.9A CN104435877A (en) 2014-11-10 2014-11-10 Radix-puerariae-containing pharmaceutical composition for reducing blood fat

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410626431.9A CN104435877A (en) 2014-11-10 2014-11-10 Radix-puerariae-containing pharmaceutical composition for reducing blood fat

Publications (1)

Publication Number Publication Date
CN104435877A true CN104435877A (en) 2015-03-25

Family

ID=52883138

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410626431.9A Pending CN104435877A (en) 2014-11-10 2014-11-10 Radix-puerariae-containing pharmaceutical composition for reducing blood fat

Country Status (1)

Country Link
CN (1) CN104435877A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101020013A (en) * 2007-03-16 2007-08-22 郭云华 Hypoglycemic and antilipemic health product and its prepn
CN101623477A (en) * 2008-07-13 2010-01-13 北京天骄奥特奇中蒙药工程技术研究有限公司 Novel process for Chinese medicinal composition for reducing blood fat and method for preparing novel formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101020013A (en) * 2007-03-16 2007-08-22 郭云华 Hypoglycemic and antilipemic health product and its prepn
CN101623477A (en) * 2008-07-13 2010-01-13 北京天骄奥特奇中蒙药工程技术研究有限公司 Novel process for Chinese medicinal composition for reducing blood fat and method for preparing novel formulations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
徐要君等: "浅谈高脂血症用药规律", 《中医药学报》 *
田金洲等: "《中医老年病学》", 30 September 2002, 上海科学技术出版社 *
耿彩霞，赵纪刚: "自拟降脂汤治疗高脂血症50例观察", 《河北中医》 *

Similar Documents

Publication Publication Date Title
CN101239112A (en) Chinese medicinal composition for regulating blood fat and preparation thereof
CN104013926A (en) Traditional Chinese medicine composition and application of traditional Chinese medicine composition as medicine for treating fatty liver
CN105727145A (en) Traditional Chinese medicine drug for treating spleen deficiency phlegm-dampness syndrome type hyperlipidaemia
CN101711848B (en) Chinese medicinal composition capable of adjunctively treating tumour
CN103301267B (en) Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof
CN102406724A (en) Chinese medicinal composition for treating talalgia
CN103446445B (en) Traditional Chinese medicine preparation for treating qi-yin deficiency-type chronic bronchitis and preparation method thereof
CN103610936B (en) A kind of Chinese medicine preparation and preparation method for the treatment of coronary heart disease
CN102293985B (en) Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof
JP7340113B2 (en) Chinese herbal composition and its production method and use
CN104257883A (en) Traditional Chinese medicine composition for treating leucopenia after chemotherapy
CN104435772A (en) Hawthorn-containing pharmaceutical composition for reducing blood fat
CN103394002A (en) Medicinal composition for treating cutaneous pruritus as well as preparation method and application thereof
CN103041233A (en) Pharmaceutical composition for treating infantile diarrhea and preparation method thereof
CN104306847A (en) Six-ingredient qi-tonifying capsule and preparation process thereof
CN104587300A (en) Traditional Chinese medicine composition for treating acute leukemia and preparation method of traditional Chinese medicine composition
CN104435205A (en) Salvia-miltiorrhiza-containing pharmaceutical composition for reducing blood fat
CN104888132A (en) Traditional Chinese medicine composition for treatment of chronic gastritis
CN104435877A (en) Radix-puerariae-containing pharmaceutical composition for reducing blood fat
CN104435690A (en) Traditional Chinese medicine composition with effects of invigorating spleen and kidney and preparation method thereof
CN103816470A (en) Traditional Chinese medicine composition for treating anorexia
CN103585414A (en) Pharmaceutical composition for treating sciatica and osteoporosis
CN102100814A (en) Method for preparing nanometer traditional Chinese medicine for treating severe asthma and production method thereof
CN104367947A (en) Rhizoma panacis majoris-containing pharmaceutical composition for lowering blood fat
CN100571739C (en) Herbal mixture of treatment cardiovascular disease and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150325

WD01 Invention patent application deemed withdrawn after publication